APO-MONTELUKAST TABLET (CHEWABLE)
Country: Kanada
Lingwa: Ingliż
Sors: Health Canada
Karatteristiċi tal-prodott
(SPC)
02-11-2021
Xi dokumenti għal dan il-prodott mhumiex disponibbli bħalissa, tista 'tibgħat talba lis-servizz tal-konsumatur tagħna u aħna ninnotifikawkom malli nkunu nistgħu niksbuhom.
Ibgħat talba.
Ibgħat talba.
Ingredjent attiv:
MONTELUKAST (MONTELUKAST SODIUM)
Disponibbli minn:
APOTEX INC
Kodiċi ATC:
R03DC03
INN (Isem Internazzjonali):
MONTELUKAST
Dożaġġ:
5MG
Għamla farmaċewtika:
TABLET (CHEWABLE)
Kompożizzjoni:
MONTELUKAST (MONTELUKAST SODIUM) 5MG
Rotta amministrattiva:
ORAL
Unitajiet fil-pakkett:
15G/50G
Tip ta 'preskrizzjoni:
Prescription
Żona terapewtika:
LEUKOTRIENE MODIFIERS
Sommarju tal-prodott:
Active ingredient group (AIG) number: 0133823001; AHFS:
L-istatus ta 'awtorizzazzjoni:
APPROVED
Data ta 'l-awtorizzazzjoni:
2019-04-26
Karatteristiċi tal-prodott
Page 1 of 31
PRODUCT MONOGRAPH
PR
APO-MONTELUKAST
montelukast (as montelukast sodium)
4 mg and 5 mg chewable tablets
Leukotriene Receptor Antagonist
APOTEX INC.
DATE OF REVISION:
150 Signet Drive
November 2, 2021
Toronto, Ontario
M9L 1T9
SUBMISSION CONTROL NO.: 256160
Page 2 of 31
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
............................................................. 3
SUMMARY PRODUCT INFORMATION
................................................................................
3
INDICATIONS AND CLINICAL USE
.....................................................................................
3
CONTRAINDICATIONS
.......................................................................................................
4
WARNINGS AND PRECAUTIONS
........................................................................................
4
ADVERSE
REACTIONS........................................................................................................
7
DRUG INTERACTIONS
.......................................................................................................10
DOSAGE AND
ADMINISTRATION......................................................................................12
OVERDOSAGE
...................................................................................................................13
ACTION AND CLINICAL
PHARMACOLOGY.......................................................................13
STORAGE AND STABILITY
................................................................................................17
DOSAGE FORMS, COMPOSITION AND
PACKAGING..........................................................17
PART II: SCIENTIFIC
INFORMATION.................................................................................18
PHARMACEUTICAL INFORMATION
..................................................................................18
CLINICAL
TRIALS..............................................................................................................19
TOX
Aqra d-dokument sħiħ
